TRIANGLE

TRIANGLE Regimen

The TRIANGLE regimen is a relatively new, aggressive induction strategy for younger patients with MCL.

• Protocol Structure: It consists of alternating cycles of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) combined with a covalent BTK inhibitor (BTKi) and R-DHA + platinum.
• BTK Inhibitor Selection: Ibrutinib is a Category 2A recommendation in this setting, while acalabrutinib or zanubrutinib are considered Category 2B options.
• Consolidation and Maintenance: Clinical data from the TRIANGLE study demonstrated the benefit of adding a covalent BTKi continuously for 2 years of maintenance following ASCT.